Published in Law and Health Weekly, December 11th, 2004
Treatment response in this study of treatment- experienced patients was defined as a 1 log(10) or greater decrease in viral load from baseline. Tipranavir is an investigational non-peptidic protease inhibitor that requires boosting with low-dose ritonavir. These data were presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.